Nuvig Therapeutics Announces $161 Million Series B Financing, Plus Its Progression to Phase 2 with Novel, Second-Generation Immunomodulator
December 5, 2024
0
Nuvig Therapeutics in the NEWS Nuvig Therapeutics – a privately held biotech company, developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, announced the closing of a $161 million Series B financing. The financing was co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities (formerly Cowen Healthcare Investments), and Norwest Venture Partners, with participation from new investors, B Capital, Leaps by …